A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

BACKGROUND: Sunitinib treatment results in a compensatory increase in plasma VEGF levels. Acute withdrawal of sunitinib results in a proliferative withdrawal flare, primarily due to elevated VEGF levels. Concurrent sunitinib plus bevacizumab is poorly tolerated with high (37 %) incidence of microang...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bruce, Justine Yang, Kolesar, Jill M., Hammers, Hans, Stein, Mark N., Carmichael, Lakeesha, Eickhoff, Jens, Johnston, Susan A., Binger, Kimberly A., Heideman, Jennifer L., Perlman, Scott B., Jeraj, Robert, Liu, Glenn
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4200479/
https://ncbi.nlm.nih.gov/pubmed/24414551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2373-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak